Ocuphire Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Ocuphire Pharma has a total shareholder equity of $49.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $53.9M and $4.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$50.52m |
| Equity | US$49.91m |
| Total liabilities | US$4.04m |
| Total assets | US$53.95m |
Recent financial health updates
We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27
We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11Recent updates
Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch
May 02Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11Ocuphire drops 11% on $15M at-the money direct offering
Jun 04Ocuphire Pharma EPS beats by $0.36
May 07Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?
Feb 08Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition
Jan 06Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances
Jan 05Financial Position Analysis
Short Term Liabilities: OCUP's short term assets ($53.9M) exceed its short term liabilities ($4.0M).
Long Term Liabilities: OCUP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: OCUP is debt free.
Reducing Debt: OCUP currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCUP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: OCUP has sufficient cash runway for 3 years if free cash flow continues to grow at historical rates of 27.9% each year.